Old Web
English
Sign In
Acemap
>
authorDetail
>
Mary Elizabeth Jones
Mary Elizabeth Jones
Merck & Co.
Pharmacology
Medicine
Myelogenous
Refractory
Dosing
2
Papers
6
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors.
2017
Journal of Clinical Oncology
Irene Brana
Jhanelle E. Gray
Paul Haluska
Raanan Berger
Talia Golan
Mary Elizabeth Jones
Alexandra Gunchenko
Jonathan D. Cheng
Lillian L. Siu
Show All
Source
Cite
Save
Citations (1)
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).
2015
Journal of Clinical Oncology
Farhad Ravandi
Ivana Gojo
Mrinal M Patnaik
Mark D. Minden
Hagop M. Kantarjian
Amy O. Johnson-Levonas
Craig Fancourt
Raymond Lam
Amy Meister
Mary Elizabeth Jones
Ramon Kemp
Clayton D. Knox
Shelonitda Rose
Payal Shah Patel
Raoul Tibes
Show All
Source
Cite
Save
Citations (5)
1